On July 31, Merck announced that the FDA approved Keytruda monotherapy for patients with recurrent locally advanced or metastatic esophageal squamous cell carcinoma who had previously received at least one line of systemic PD-L1 expression (CPS ≥ 10). This approval is based primarily on data from two studies. One… Continue Reading Keytruda new indications approved, the first esophageal cancer PD-1 therapy

  Lupus erythematosus is an autoimmune inflammatory connective tissue disease. From the perspective of pathogenesis, the mainstream view is that genetic factors, environmental factors, estrogen levels and other factors interact to cause excessive proliferation of B cells in patients, resulting in a large number of autoantibodies. The antibody binds to… Continue Reading The first new drug for lupus erythematosus, Belimumab was approved for listing in China

  The prototype of the best-selling book “The Billion-Dollar Molecule” in the pharmaceutical industry is Vertex. The company, which was founded in 1989, started with $10 million in funds and can be said to be a dark horse enterprise in the pharmaceutical industry. Vertex has created three drugs with annual… Continue Reading “The Billion-Dollar Molecule” prototype Vertex’s “Next City”

  Recently, the US FDA approved Novartis’s spinal muscular atrophy (SMA) gene therapy Zolgensma, which brought dawn to SMA patients and their families, but it has once again refreshed the drug price record with a price of 2.1 million US dollars, making it the most expensive medicine in history. The… Continue Reading World Health Assembly passed the “Transparent Drug Market” resolution: will affect future drug pricing

  On April 25, Lilly announced that it is advancing the global withdrawal of the new soft tissue sarcoma drug Lartruvo (olaratumab). Lilly’s decision was mainly due to the fact that in the large phase III ANNOUNCE study after marketing, olaratumab failed to show survival benefit in both the treated… Continue Reading Lilly’s soft tissue sarcoma drug Olaratumab will withdraw from the world

  Pharmaceutical companies usually do their utmost to extend the patent protection period to prevent the listing of generic drugs in order to gain market exclusive rights. Fiercepharma recently released a list of TOP10 drugs that lost exclusive rights in the United States in 2019, listing 10 varieties from seven… Continue Reading Top10 of drugs that lost exclusive rights in the US market in 2019

  Bispecific antibody (BsAb) refers to an antibody molecule that can specifically bind two antigens or two epitopes at the same time. In theory, it can exert synergistic effect of two monoclonal antibodies, which is one of the most popular new drug research and development investment direction in the industry.… Continue Reading Bispecific antibody boom

  On February 27th, Bayer announced its 2018 financial report. The Group achieved a total revenue of 39.586 billion euros, an increase of 13.1% compared with 2017. The total revenue of the pharmaceutical business was 16.746 billion euros (-0.6%), the income from consumer health business was 5.45 billion euros (-7%),… Continue Reading Bayer 2018 earnings report: Acarbose reverse growth! New drug development is broken, the structure is about to be adjusted

  In November last year, the Financial Times discussed some of the characteristics of the transformation of the Chinese pharmaceutical industry at the “2018 Pharmaceutical & Biotechnology Summit” held in London. At the meeting, the host threw out a poll of “When do you think China might become an important… Continue Reading The new road of Chinese pharmaceutical companies

  On February 19, Intercept announced that olbecholic acid (OCA) has achieved positive results in the mid-phase analysis of the key phase III REGENERATE study of patients with nonalcoholic steatohepatitis (NASH) with grade 2 to 3 liver fibrosis. Efficacy data from the primary endpoint showed: 1) At the 18th month… Continue Reading NASH’s new drug wins its first phase III clinical victory, and Abecholic acid is about to open a $40 billion market